A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)

Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, Juan Montoro, Sara Steffanoni, Grzegorz S Nowakowski, Sara Gandini, Mara Negri, Thomas Matthew Habermann, Markus Raderer, Zhi Ming Li, Pier Luigi Zinzani, Patrick Adam, Emanuele Zucca, Giovanni Martinelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62(range 28-88)years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19% patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30%), radiotherapy in 3 (2%), antibiotics in 1 (1%) and systemic treatment in 128 (62%). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p=0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.

Original languageEnglish (US)
JournalHematological Oncology
DOIs
StateAccepted/In press - 2015

Fingerprint

Lymphoma
Retrospective Studies
Lung
Therapeutics
Disease-Free Survival
Radiotherapy
Marginal Zone B-Cell Lymphoma
Preexisting Condition Coverage
Poisons
Bronchi
Lung Diseases
Autoimmune Diseases
Smoking
Anti-Bacterial Agents
Recurrence
Survival

Keywords

  • Achromobacter (Alcaligenes) xylosoxidans
  • BALT lymphoma
  • Marginal zone lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). / Sammassimo, Simona; Pruneri, Giancarlo; Andreola, Giovanna; Montoro, Juan; Steffanoni, Sara; Nowakowski, Grzegorz S; Gandini, Sara; Negri, Mara; Habermann, Thomas Matthew; Raderer, Markus; Li, Zhi Ming; Zinzani, Pier Luigi; Adam, Patrick; Zucca, Emanuele; Martinelli, Giovanni.

In: Hematological Oncology, 2015.

Research output: Contribution to journalArticle

Sammassimo, Simona ; Pruneri, Giancarlo ; Andreola, Giovanna ; Montoro, Juan ; Steffanoni, Sara ; Nowakowski, Grzegorz S ; Gandini, Sara ; Negri, Mara ; Habermann, Thomas Matthew ; Raderer, Markus ; Li, Zhi Ming ; Zinzani, Pier Luigi ; Adam, Patrick ; Zucca, Emanuele ; Martinelli, Giovanni. / A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). In: Hematological Oncology. 2015.
@article{410362c5745148b7bada7d110a7da3db,
title = "A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)",
abstract = "Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62(range 28-88)years. Only 9{\%} had a history of exposure to toxic substances, while about 45{\%} of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19{\%} patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30{\%}), radiotherapy in 3 (2{\%}), antibiotics in 1 (1{\%}) and systemic treatment in 128 (62{\%}). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p=0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.",
keywords = "Achromobacter (Alcaligenes) xylosoxidans, BALT lymphoma, Marginal zone lymphoma",
author = "Simona Sammassimo and Giancarlo Pruneri and Giovanna Andreola and Juan Montoro and Sara Steffanoni and Nowakowski, {Grzegorz S} and Sara Gandini and Mara Negri and Habermann, {Thomas Matthew} and Markus Raderer and Li, {Zhi Ming} and Zinzani, {Pier Luigi} and Patrick Adam and Emanuele Zucca and Giovanni Martinelli",
year = "2015",
doi = "10.1002/hon.2243",
language = "English (US)",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)

AU - Sammassimo, Simona

AU - Pruneri, Giancarlo

AU - Andreola, Giovanna

AU - Montoro, Juan

AU - Steffanoni, Sara

AU - Nowakowski, Grzegorz S

AU - Gandini, Sara

AU - Negri, Mara

AU - Habermann, Thomas Matthew

AU - Raderer, Markus

AU - Li, Zhi Ming

AU - Zinzani, Pier Luigi

AU - Adam, Patrick

AU - Zucca, Emanuele

AU - Martinelli, Giovanni

PY - 2015

Y1 - 2015

N2 - Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62(range 28-88)years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19% patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30%), radiotherapy in 3 (2%), antibiotics in 1 (1%) and systemic treatment in 128 (62%). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p=0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.

AB - Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62(range 28-88)years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19% patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30%), radiotherapy in 3 (2%), antibiotics in 1 (1%) and systemic treatment in 128 (62%). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p=0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.

KW - Achromobacter (Alcaligenes) xylosoxidans

KW - BALT lymphoma

KW - Marginal zone lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84936806460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936806460&partnerID=8YFLogxK

U2 - 10.1002/hon.2243

DO - 10.1002/hon.2243

M3 - Article

C2 - 26152851

AN - SCOPUS:84936806460

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -